Skip to main content
. Author manuscript; available in PMC: 2011 May 10.
Published in final edited form as: Int J Cancer. 2010 Jul 15;127(2):257–268. doi: 10.1002/ijc.25041

Figure 3.

Figure 3

Resveratrol potentiates the effect of gemcitabine to inhibit the growth of pancreatic cancer in nude mice. (a) Schematic representation of experimental protocol described in Material and Methods. Group I was given with Vehicle (100 μL, p.o., daily) and PBS (100 μL, i.p., twice weekly), Group II was given with resveratrol (40 mg kg−1, p.o., daily), Group III was given with gemcitabine (25 mg kg−1, i.p., twice weekly), and Group IV was given with resveratrol (40 mg kg−1, p.o., daily) and gemcitabine (25 mg kg−1, i.p., twice weekly; n = 8). (b) Left panel, bioluminescence IVIS images of orthotopically implanted pancreatic tumors in live, anesthetized mice. Right panel, measurements of photons per second depicting tumor volume at various time points using live IVIS imaging at the indicated times (n = 8). (c) Necropsy photographs of mice bearing orthotopically implanted pancreatic tumors; (d) tumor volumes in mice measured on the last day of the experiment at necropsy using Vernier calipers and calculated using the formula V = 2/3πr3 (n = 6).